HOOKIPA Pharma HOOK Stock
HOOKIPA Pharma Price Chart
HOOKIPA Pharma HOOK Financial and Trading Overview
| HOOKIPA Pharma stock price | 1.15 USD |
| Previous Close | 1.14 USD |
| Open | 1.09 USD |
| Bid | 1.09 USD x 25100 |
| Ask | 1.14 USD x 26200 |
| Day's Range | 1.09 - 1.14 USD |
| 52 Week Range | 0.81 - 1.65 USD |
| Volume | 3.13K USD |
| Avg. Volume | 12.54K USD |
| Market Cap | 14.11M USD |
| Beta (5Y Monthly) | 0.832 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.83 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
HOOK Valuation Measures
| Enterprise Value | -25232354 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.20994475 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.5088452 |
| Price/Book (mrq) | 0.4200442 |
| Enterprise Value/Revenue | -2.698 |
| Enterprise Value/EBITDA | 0.349 |
Trading Information
HOOKIPA Pharma Stock Price History
| Beta (5Y Monthly) | 0.832 |
| 52-Week Change | -27.84% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 1.65 USD |
| 52 Week Low | 0.81 USD |
| 50-Day Moving Average | 1.14 USD |
| 200-Day Moving Average | 0.98 USD |
HOOK Share Statistics
| Avg. Volume (3 month) | 12.54K USD |
| Avg. Daily Volume (10-Days) | 11.35K USD |
| Shares Outstanding | 9.98M |
| Float | 12.34M |
| Short Ratio | 0.57 |
| % Held by Insiders | 0.12% |
| % Held by Institutions | 3.16% |
| Shares Short | 35.8K |
| Short % of Float | 0.44% |
| Short % of Shares Outstanding | 0.28% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | March 31, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -885.27% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -45.20% |
| Return on Equity (ttm) | -105.78% |
Income Statement
| Revenue (ttm) | 9.35M USD |
| Revenue Per Share (ttm) | 0.75 USD |
| Quarterly Revenue Growth (yoy) | -94.50% |
| Gross Profit (ttm) | -50473000 USD |
| EBITDA | -72401000 USD |
| Net Income Avi to Common (ttm) | -73313000 USD |
| Diluted EPS (ttm) | -4.83 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 40.28M USD |
| Total Cash Per Share (mrq) | 3.18 USD |
| Total Debt (mrq) | 596K USD |
| Total Debt/Equity (mrq) | 1.75 USD |
| Current Ratio (mrq) | 3.612 |
| Book Value Per Share (mrq) | 2.714 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -52770000 USD |
| Levered Free Cash Flow (ttm) | -32811376 USD |
Profile of HOOKIPA Pharma
| Country | United States |
| State | NY |
| City | New York |
| Address | 350 Fifth Avenue |
| ZIP | 10118 |
| Phone | 431 890 6360 |
| Website | https://www.hookipapharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 82 |
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
Q&A For HOOKIPA Pharma Stock
What is a current HOOK stock price?
HOOKIPA Pharma HOOK stock price today per share is 1.15 USD.
How to purchase HOOKIPA Pharma stock?
You can buy HOOK shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for HOOKIPA Pharma?
The stock symbol or ticker of HOOKIPA Pharma is HOOK.
Which industry does the HOOKIPA Pharma company belong to?
The HOOKIPA Pharma industry is Biotechnology.
How many shares does HOOKIPA Pharma have in circulation?
The max supply of HOOKIPA Pharma shares is 12.38M.
What is HOOKIPA Pharma Price to Earnings Ratio (PE Ratio)?
HOOKIPA Pharma PE Ratio is now.
What was HOOKIPA Pharma earnings per share over the trailing 12 months (TTM)?
HOOKIPA Pharma EPS is -4.83 USD over the trailing 12 months.
Which sector does the HOOKIPA Pharma company belong to?
The HOOKIPA Pharma sector is Healthcare.
HOOKIPA Pharma HOOK included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Global Select Market Com NQGS | 13180.97 USD — |
-0.87
|
— — | 13139.79 USD — | 13316.81 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}